The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis

Contemporary Clinical Trials
Timothy AksamitRobert Wilson

Abstract

The primary goals of long-term disease management in non-cystic fibrosis bronchiectasis (NCFB) are to reduce the number of exacerbations, and improve quality of life. However, currently no therapies are licensed for this. Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) has potential to be the first long-term intermittent therapy approved to reduce exacerbations in NCFB patients. The RESPIRE programme consists of two international phase III prospective, parallel-group, randomized, double-blinded, multicentre, placebo-controlled trials of the same design. Adult patients with idiopathic or post-infectious NCFB, a history of ≥2 exacerbations in the previous 12months, and positive sputum culture for one of seven pre-specified pathogens, undergo stratified randomization 2:1 to receive twice-daily Ciprofloxacin DPI 32.5mg or placebo using a pocket-sized inhaler in one of two regimens: 28days on/off treatment or 14days on/off treatment. The treatment period is 48weeks plus an 8-week follow-up after the last dose. The primary efficacy endpoints are time to first exacerbation after treatment initiation and frequency of exacerbations using a stringent definition of exacerbation. Secondary endpoints, including frequency of even...Continue Reading

References

Jun 17, 1993·The New England Journal of Medicine·B W RamseyM A McBurnie
Aug 1, 1997·American Journal of Respiratory and Critical Care Medicine·C B WilsonR Wilson
Aug 10, 2000·American Journal of Respiratory and Critical Care Medicine·A F BarkerJ Quan
Apr 10, 2009·The European Respiratory Journal·M R LoebingerR Wilson
Mar 23, 2010·Respiratory Medicine·Helen J Roberts, Richard Hubbard
Jul 22, 2010·Thorax·M C PasteurUNKNOWN British Thoracic Society Bronchiectasis non-CF Guideline Group
Sep 28, 2010·American Journal of Respiratory and Critical Care Medicine·Maeve P MurrayAdam T Hill
Jun 30, 2012·American Journal of Respiratory and Critical Care Medicine·James D ChalmersAdam T Hill
Sep 29, 2012·The European Respiratory Journal·Robert WilsonBarbara Hampel
Dec 18, 2012·Thorax·Anthony De SoyzaUNKNOWN Bronchiectasis Research & Academic Network
Jun 4, 2013·QJM : Monthly Journal of the Association of Physicians·M J McDonnellR M Rutherford
Aug 1, 2013·American Journal of Respiratory and Critical Care Medicine·Pamela J McShaneMary E Strek
Nov 16, 2013·The European Respiratory Journal·Miguel Á Martínez-GarcíaCasilda Olveira
Dec 18, 2013·American Journal of Respiratory and Critical Care Medicine·James D ChalmersAdam T Hill
Jan 15, 2014·Respirology : Official Journal of the Asian Pacific Society of Respirology·Qibiao WuXiqiao Zhou
Mar 15, 2014·American Journal of Respiratory and Critical Care Medicine·Charles S HaworthDiana Bilton
Apr 24, 2014·American Journal of Respiratory and Critical Care Medicine·Mark L Metersky, Anne E O'Donnell
Sep 7, 2014·Advanced Drug Delivery Reviews·Jeffry Weers
Sep 24, 2014·Thorax·Diana BiltonUNKNOWN B-305 Study Investigators
Nov 19, 2014·PloS One·Wei-jie GuanNan-shan Zhong
Dec 3, 2014·Advanced Drug Delivery Reviews·Patrick A Flume, Donald R VanDevanter
Feb 6, 2015·The European Respiratory Journal·John R HurstUNKNOWN BRONCH-UK Consortium
Mar 21, 2015·The European Respiratory Journal·James D ChalmersFrancesco Blasi
Sep 12, 2015·Annals of the American Thoracic Society·Simon FinchJames D Chalmers
Dec 22, 2015·BMJ Open Respiratory Research·Henry L DorkinMargarita Criollo
Feb 10, 2016·Clinics in Chest Medicine·Wael ElMaraachliAngela C C Wang

❮ Previous
Next ❯

Citations

Feb 8, 2018·The Cochrane Database of Systematic Reviews·Carol KellySally Spencer
Jan 23, 2018·American Journal of Respiratory and Critical Care Medicine·James D ChalmersMelissa J McDonnell
Jun 4, 2018·The Cochrane Database of Systematic Reviews·Tim DonovanSally Spencer
Jan 17, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Katherine O'NeillJudy M Bradley
Feb 2, 2018·The European Respiratory Journal·Miguel Angel Martinez-García
May 31, 2019·AAPS PharmSciTech·Frederic TewesHugh D C Smyth
Mar 1, 2018·Current Opinion in Infectious Diseases·Anne E O'Donnell
Aug 14, 2015·The Cochrane Database of Systematic Reviews·Khin HninBrian J Smith
Jul 4, 2020·Therapeutic Advances in Respiratory Disease·Meng-Jiao Xu, Bing Dai
Apr 9, 2019·Statistical Methods in Medical Research·Qiqi DengMing-Hui Chen
Jun 6, 2021·International Journal of Pharmaceutics·Li DingZhengrong Cui
Jan 6, 2022·The Cochrane Database of Systematic Reviews·Sally SpencerPeter Leadbetter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.